|
業務類別
|
-- |
|
業務概覽
|
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs. |
| 公司地址
| 72 Hammersmith Road, London, GBR, W14 8TH |
| 電話號碼
| +44 2034576900 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.silence-therapeutics.com |
| 員工數量
| 116 |
| Ms. Rhonda L. Hellums |
Director, Executive Vice President, Chief Financial Officer and Principal Accounting Officer |
英鎊 466.01K |
05/03/2026 |
| Dr. Steven Joseph Romano, M.D. |
Head of Research and Development |
英鎊 465.75K |
16/05/2025 |
| Mr. Iain Gladstone Ross |
Chairman of the Board and Interim Principal Executive Officer |
-- |
05/03/2026 |
|
|
| Mr. Timothy Mcinerney |
Director |
05/03/2026 |
| Mr. James Lawrence Ede-Golightly |
Independent Director |
05/03/2026 |
| Ms. Rhonda L. Hellums |
Director, Executive Vice President, Chief Financial Officer and Principal Accounting Officer |
05/03/2026 |
| Mr. David Jakob Lemus |
Independent Director |
05/03/2026 |
| Mr. Iain Gladstone Ross |
Chairman of the Board and Interim Principal Executive Officer |
05/03/2026 |
|
|
|
|
